Ambros Therapeutics Launches With $125 Million Series A
New York – December 16, 2025 – Cooley advised Ambros Therapeutics, a clinical-stage biotechnology company advancing late-stage therapies for severe, underserved diseases beginning with neridronate for Complex Regional Pain Syndrome Type 1 (CRPS-1), on its oversubscribed $125 million Series A financing and its strategic collaboration agreement with Abiogen Pharma, under which Ambros obtained exclusive rights to neridronate in North America with an option for broader market expansion. The financing is expected to support the neridronate pivotal Phase 3 clinical trial in CRPS-1 (CRPS-RISE) and related regulatory preparations and pre-commercial activities.
RA Capital Management and Patient Square Capital’s platform Enavate Sciences co-led the round with additional participation from Abiogen Pharma, Janus Henderson Investors, Arkin Bio, Balyasny Asset Management, Transhuman Capital, Adage Capital Partners LP and other dedicated life sciences investors.
Lawyers Jason Kent, Geoffrey Spolyar, Wade Andrews, Arda Tekin, Alex Abelson and Virat Gupta led the Cooley team advising Ambros.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.